What are the manufacturers of 0.01% atropine sulfate eye drops?

0.01% Atropine Sulfate Eye Drops (EIKANCE), as an innovative drug to control the development of myopia, is jointly developed and produced by several internationally renowned pharmaceutical companies. The drug was first jointly developed by a number of pharmaceutical companies in the United States and Japan. It relies on mature pharmaceutical technology and strict quality control to ensure the high purity and safety of the product. Major manufacturers include Eisai Co., Ltd. in Japan and pharmaceutical companies in the United States. These companies have rich R&D experience and good market reputation in the field of ophthalmic drugs. As a leading global pharmaceutical company, Eisai is known for its R&D capabilities in the fields of neuroscience and ophthalmology. The atropine sulfate eye drops it produces have stable quality, comply with international pharmacopoeia standards, and are widely recognized by clinicians and patients.

In addition, some pharmaceutical companies in Asia are also actively promoting the localized production and sales of EIKANCE, in compliance with international standards, and to meet the needs of different markets. These manufacturers usually use advanced sterile production processes and strict quality management systems to ensure that drugs remain active and safe during transportation and storage. In addition, manufacturers also pay attention to packaging design to facilitate the operation of patients, especially children, and improve patient compliance.

Manufacturers not only focus on the quality of the drug itself, but also actively promote relevant clinical research and market education to help doctors and patients understand the mechanism and advantages of low-concentration atropine in myopia control. At the same time, they cooperate with the drug regulatory authorities of various countries to complete drug registration and approval to ensure that products enter the market legally and compliantly. At present, EIKANCE has been approved in many countries and regions and has been officially launched for sale. The manufacturer ensures the timely supply of drugs through the global sales network.

Reference materials:https://www.medsafe.govt.nz/profs/datasheet/e/EikanceEyeDrops.pdf